Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALTABAX vs BACI-RX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
FDA-approved for topical treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes in patients aged 9 months and older
FDA-approved: Treatment of superficial skin infections caused by susceptible organisms,Off-label: Ophthalmic infections (conjunctivitis, blepharitis), nasal carriage of Staphylococcus aureus
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 m L/min.
Retapamulin undergoes hepatic metabolism primarily via cytochrome P450 (CYP) isoenzymes, including CYP3A4, and is excreted in feces and urine.
Bacitracin is not systemically absorbed after topical administration; no significant hepatic metabolism. Systemic absorption can occur with large topical doses or use on denuded skin, and it is excreted primarily unchanged by the kidneys.
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
Retapamulin is approximately 94% bound to human plasma proteins, primarily albumin.
Approximately 10-20% bound to serum proteins (albumin).
Volume of distribution after IV administration is approximately 3.1 L/kg, indicating extensive tissue distribution.
0.25-0.4 L/kg. Low Vd indicates distribution primarily to extracellular fluid; minimal tissue penetration except renal cortex.
Systemic bioavailability after topical application is low and highly variable, with mean values <2% in adults.
Intramuscular: ~100% (rapid and complete); oral: negligible (<1%) due to poor absorption; topical: variable, minimal systemic absorption (<5% with intact skin).
No dose adjustment required for renal impairment as systemic absorption is negligible.
No adjustment required; bacitracin is not significantly renally eliminated.
No dose adjustment required for hepatic impairment as systemic absorption is negligible.
No adjustment required; bacitracin is not hepatically metabolized.
Children 9 months and older: Apply 1% ointment to affected area twice daily for 5 days. Maximum treatment area 100 cm². For children under 9 months: safety and efficacy not established.
Weight-based dosing as per standard protocol: 1-2 units/kg intramuscularly every 2-4 hours; adjust based on factor levels.
No specific dose adjustment required. Use same as adult dosing due to minimal systemic absorption.
Use standard dosing with caution for renal function; assess GFR and adjust if impaired.
No black box warnings.
No FDA black box warning.
Not for use on mucous membranes (e.g., eyes, mouth, vagina).,May cause application site reactions (e.g., pruritus, erythema, pain).,Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including retapamulin.,Prolonged use may result in overgrowth of nonsusceptible organisms.
Nephrotoxicity with systemic absorption; avoid use on large surface areas or deep wounds; hypersensitivity reactions; potential for superinfection; not for ophthalmic use unless specifically formulated.
Hypersensitivity to retapamulin or any component of the formulation.
Hypersensitivity to bacitracin or any component of the formulation; severe renal impairment (if systemic absorption is possible).
None known. Topical application with negligible systemic absorption; no dietary restrictions.
No known food interactions with topical bacitracin.
No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 times MRHD) showed no fetal harm. However, systemic absorption after topical application is minimal, so fetal exposure is negligible. Risk cannot be ruled out; classify as pregnancy category B.
First trimester: No evidence of teratogenicity in animal studies; limited human data. Second and third trimesters: No known fetal risks; use only if clearly needed.
Not known if retapamulin is excreted in human milk. Systemic absorption is negligible after topical use, so risk to infant is likely low. M/P ratio not determined. Caution if applied to breast area to avoid infant ingestion.
Unknown if excreted in human milk; M/P ratio not available. Caution is advised; consider temporary discontinuation of breastfeeding or drug based on importance to mother.
No dose adjustment needed. Pharmacokinetics unchanged as systemic absorption is minimal (<1%) and not affected by pregnancy. Standard dosing: apply thin layer to affected area twice daily for 5 days.
No dose adjustment required due to pregnancy-related pharmacokinetic changes; dose based on indication and renal function.
Retapamulin (Altabax) is a topical pleuromutilin antibiotic indicated for impetigo due to S. aureus or S. pyogenes. Apply to lesions twice daily for 5 days. Avoid contact with eyes, mouth, or mucous membranes. No systemic absorption significant; safe for use in children ≥9 months. Do not use on open wounds or burns. Monitor for local irritation; discontinue if hypersensitivity occurs.
BACI-RX (bacitracin) is a topical antibiotic effective against gram-positive organisms. Avoid systemic use due to nephrotoxicity. Apply thin layer; hypersensitivity reactions possible. Not for ophthalmic use unless specified. Monitor for superinfection with prolonged use.
Apply a thin layer to the affected area twice daily for 5 days, even if symptoms improve.,Wash hands before and after application unless treating hand lesions.,Do not cover the area with bandages unless instructed by your doctor.,Avoid getting the ointment in your eyes, nose, mouth, or on vaginal area.,Stop use and inform your doctor if you develop severe irritation, redness, or swelling.,Store at room temperature away from heat and moisture.
Apply a thin layer to affected area as directed.,Wash hands before and after application unless treating hands.,Do not use on large areas of skin or deep puncture wounds.,Stop use and consult provider if rash or irritation develops.,Do not use in eyes or mouth unless specifically prescribed.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALTABAX vs BACI-RX, answered by our medical review team.
ALTABAX is a Topical Antibiotic that works by Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.. BACI-RX is a Topical Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALTABAX and BACI-RX depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALTABAX is: 1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².. The standard adult dose of BACI-RX is: 1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALTABAX and BACI-RX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALTABAX is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies: oral doses up to 50 mg/kg/day in rats (0.8 times MRHD based on AUC) and 40 mg/kg/day in rabbits (1.6 time. BACI-RX is classified as Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second and third trimesters: No known fetal risks; use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.